Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBMG NASDAQ:HARP NASDAQ:JNCE NASDAQ:PDLI NASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBMGCellular Biomedicine Group$19.68$11.48▼$19.75$384.69M1.35129,776 shs8,375 shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/AJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsPDLIPDL BioPharma$2.47$2.47$2.09▼$3.86N/AN/AN/AN/ASTROSutro Biopharma$1.06-8.6%$0.91$0.52▼$4.60$98.34M1.611.49 million shs785,274 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBMGCellular Biomedicine Group0.00%0.00%0.00%0.00%0.00%HARPHarpoon Therapeutics0.00%0.00%0.00%0.00%0.00%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%PDLIPDL BioPharma0.00%0.00%0.00%0.00%0.00%STROSutro Biopharma-8.62%+20.36%+27.96%+19.48%-69.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBMGCellular Biomedicine Group$19.68$11.48▼$19.75$384.69M1.35129,776 shs8,375 shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/AJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsPDLIPDL BioPharma$2.47$2.47$2.09▼$3.86N/AN/AN/AN/ASTROSutro Biopharma$1.06-8.6%$0.91$0.52▼$4.60$98.34M1.611.49 million shs785,274 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBMGCellular Biomedicine Group0.00%0.00%0.00%0.00%0.00%HARPHarpoon Therapeutics0.00%0.00%0.00%0.00%0.00%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%PDLIPDL BioPharma0.00%0.00%0.00%0.00%0.00%STROSutro Biopharma-8.62%+20.36%+27.96%+19.48%-69.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBMGCellular Biomedicine Group 0.00N/AN/AN/AHARPHarpoon Therapeutics 0.00N/AN/AN/AJNCEJounce Therapeutics 0.00N/AN/AN/APDLIPDL BioPharma 0.00N/AN/AN/ASTROSutro Biopharma 2.00Hold$4.47321.38% UpsideCurrent Analyst Ratings BreakdownLatest JNCE, PDLI, CBMG, HARP, and STRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025STROSutro BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025STROSutro BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/12/2025STROSutro BiopharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $3.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBMGCellular Biomedicine Group$340K0.00N/AN/A$2.89 per share0.00HARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53PDLIPDL BioPharmaN/AN/AN/AN/AN/AN/ASTROSutro Biopharma$62.04M1.45N/AN/A$0.54 per share1.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBMGCellular Biomedicine Group-$49.98MN/AN/AN/AN/AN/A-144.80%-61.68%N/AHARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/AJNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/APDLIPDL BioPharmaN/A$0.1913.00∞N/AN/AN/AN/AN/ASTROSutro Biopharma-$227.46M-$2.53N/AN/AN/A-201.32%-852.70%-58.67%11/12/2025 (Estimated)Latest JNCE, PDLI, CBMG, HARP, and STRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025STROSutro Biopharma-$0.39N/AN/AN/AN/AN/A8/7/2025Q2 2025STROSutro Biopharma-$0.39-$0.14+$0.25-$0.14$14.55 million$63.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBMGCellular Biomedicine GroupN/AN/AN/AN/AN/AHARPHarpoon TherapeuticsN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/APDLIPDL BioPharmaN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBMGCellular Biomedicine GroupN/A0.470.47HARPHarpoon TherapeuticsN/A1.891.89JNCEJounce TherapeuticsN/A8.378.37PDLIPDL BioPharmaN/AN/AN/ASTROSutro BiopharmaN/A3.123.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBMGCellular Biomedicine Group21.98%HARPHarpoon Therapeutics74.01%JNCEJounce Therapeutics80.66%PDLIPDL BioPharmaN/ASTROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipCBMGCellular Biomedicine Group8.50%HARPHarpoon Therapeutics17.00%JNCEJounce Therapeutics6.92%PDLIPDL BioPharma2.20%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBMGCellular Biomedicine Group21719.48 millionN/AOptionableHARPHarpoon Therapeutics5316.93 million14.05 millionOptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionablePDLIPDL BioPharma109N/AN/AOptionableSTROSutro Biopharma24084.77 million81.72 millionOptionableJNCE, PDLI, CBMG, HARP, and STRO HeadlinesRecent News About These CompaniesSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Hold" by AnalystsOctober 19, 2025 | marketbeat.comInsider Buying: Sutro Biopharma (NASDAQ:STRO) Insider Buys 12,504 Shares of StockOctober 17, 2025 | marketbeat.comHans-Peter Gerber Purchases 17,000 Shares of Sutro Biopharma (NASDAQ:STRO) StockOctober 17, 2025 | marketbeat.comGregory Chow Acquires 19,750 Shares of Sutro Biopharma (NASDAQ:STRO) StockOctober 17, 2025 | marketbeat.comInsider Buying: Sutro Biopharma (NASDAQ:STRO) Director Acquires 50,000 Shares of StockOctober 17, 2025 | marketbeat.comDavid Pauling Purchases 12,504 Shares of Sutro Biopharma (NASDAQ:STRO) StockOctober 17, 2025 | insidertrades.comSutro Biopharma's (STRO) "Sell (E+)" Rating Reiterated at Weiss RatingsOctober 9, 2025 | marketbeat.comSutro Biopharma trims workforce again to extend cash runwayOctober 1, 2025 | thepharmaletter.comTSutro Makes Deeper Cuts To Extend Runway Into 2027, Reach Key Data ReadoutOctober 1, 2025 | biospace.comBSutro Biopharma announces restructuring, workforce reduction of about 33%September 29, 2025 | msn.comSutro Biopharma stock jumps after restructuring to extend cash runwaySeptember 29, 2025 | za.investing.comSutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key MilestonesSeptember 29, 2025 | globenewswire.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 24, 2025 | marketbeat.comSutro Biopharma price target lowered to $4 from $7 at JefferiesSeptember 9, 2025 | msn.comVaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal DiseaseSeptember 3, 2025 | quiverquant.comQSutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial CancersAugust 20, 2025 | msn.comSutro Biopharma (STRO) Gets a Buy from Truist FinancialAugust 14, 2025 | theglobeandmail.comSutro Biopharma price target lowered to $3 from $4 at Wells FargoAugust 12, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO) and Relay Therapeutics (RLAY)August 9, 2025 | theglobeandmail.comSutro Biopharma, Inc.: Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 8, 2025 | finanznachrichten.deSutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue EstimatesAugust 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThor Industries Tracking for New Highs in 2026By Thomas Hughes | September 25, 2025Best Stocks Under $15? 3 Low-Priced Picks With UpsideBy Nathan Reiff | October 6, 20253 Utilities Plays You Can Lean on During VolatilityBy Nathan Reiff | October 15, 2025Analysts Think These Stocks Could More Than DoubleBy Nathan Reiff | October 22, 20255 Stocks and ETFs to Weather Volatility as Trade Tensions RiseBy Ryan Hasson | October 13, 2025JNCE, PDLI, CBMG, HARP, and STRO Company DescriptionsCellular Biomedicine Group NASDAQ:CBMGCellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Harpoon Therapeutics NASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.Jounce Therapeutics NASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.PDL BioPharma NASDAQ:PDLIPDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.Sutro Biopharma NASDAQ:STRO$1.06 -0.10 (-8.62%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$1.04 -0.02 (-1.42%) As of 10/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
